AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Event Brief of Q2 2004 Celgene Corp. Earnings Conference Call - Final.
(From Fair Disclosure Wire)
CORPORATE PARTICIPANTS . Bob Hugin, Celgene Corp., CFO & SVP . John Jackson, Celgene Corp., Chairman & CEO . Sol Barer, Celgene Corp., President & COO OVERVIEW CELG reported 2Q04 total revenue of $87.8m, up over 30% YoverY. Thalomid sales increased 36% YoverY and almost 8% sequentially. Net income totaled $12.4m or $0.14 per diluted share; $0.03 above consensus. CELG is raising its full year EPS target to $0.50-0.60 per diluted share, with full year Thalomid targets raised to $295-305m. CELG is also raising its total FY04 revenue targets to $370-390m. Q&A Focus: Clinical trial data, FDA approvals, guidance. FINANCIAL DATA A. Key Data ...
- CELGENE Corp.(multiple myeloma treatment gets orphan drug status)(Brief Article)
- Magazine article from: Chemical Market Reporter October 15, 2001 700+ words
CELGENE Corp.'s Revimid, an oral, small molecule analog of thalidomide, for multiple myeloma, has been granted orphan drug status by the FDA.
- Celgene Corp. (Active Pharmaceutical Ingredient Watch).(Food and Drug...
- Magazine article from: Chemical Market Reporter March 18, 2002 700+ words
CELGENE Corp.'s application to market leprosy drug Thalomid (thalidomide) for multiple myeloma will be delayed by at least two years as the FDA has required Celgene to conduct a Phase III trial.
- Celgene Corp. Review in Progress.
- Press release article from: M2 Presswire April 22, 2008 700+ words
...2008-MG Strategies: Celgene Corp. Review in Progress...2008, we have added Celgene Corp. (NASDAQ: CELG...publicly traded companies Celgene Corp. started the day down...with newly diagnosed multiple myeloma. In June 2007, the...
- Progressive Following on Celgene Corp.
- Press release article from: M2 Presswire April 21, 2008 700+ words
...Progressive Following on Celgene Corp.(C)1994-2008...progressive review Celgene Corp. (NASDAQ:CELG...prospective companies therein Celgene Corp. was among those that...with newly diagnosed multiple myeloma. In June 2007, the...
- Begins Preliminary Research on Celgene Corp.
- Press release article from: M2 Presswire December 11, 2007 700+ words
...For future reports on Celgene Corp. and other growth...Target_Report.pdf Celgene Corp. entered mid trading...and sank shares of Celgene Corp., a Friedman Billings...as a treatment for multiple myeloma, a cancer affecting...
- Celgene Corp. Debuts at Top of Business 2.0's 2006 List of 100 Fastest Growing...
- Press release article from: Business Wire May 24, 2006 700+ words
...is biotech company Celgene Corp., followed by Red...top ranked company, Celgene Corp. Other dominant sectors...s list: --1. Celgene Corp. (CELG), Summit...treatment for leprosy and multiple myeloma. --2. Red Hat...
- Celgene Corp. Issued Additional U.S. Patent For IMiD Pipeline.(immunomodulatory...
- Newspaper article from: Immunotherapy Weekly December 26, 2001 700+ words
...NewsRx.net) -- Celgene Corp. has been issued...treatment for refractory multiple myeloma in a Phase I/II...medical officer of Celgene Corp. "We expect to initiate...and proliferation of multiple myeloma cells. Celgene...
- MedImmune In-Licenses Novel Inflammatory Disease Target and The Year in Review,...
- Press release article from: M2 Presswire December 29, 2006 700+ words
...Target and The Year in Review, Celgene Corp.(C)1994-2006 M2 COMMUNICATIONS...ImClone perform in 2007. Shares of Celgene Corp. (Nasdaq:CELG) soared in...Thalidomide to treat newly diagnosed multiple myeloma, and the company moved to the...